Exploring a new treatment pathway for a type of lymphoma
Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy
This study is looking at a specific pathway in a type of lymphoma called Anaplastic Large Cell Lymphoma (ALCL) to find new ways to treat patients, especially those with the ALK- subtype and those affected by ALCL related to breast implants, so that future treatments can be more effective and less harsh.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11067841 on NIH RePORTER |
What this research studies
This research investigates the IL-1R pathway in Anaplastic Large Cell Lymphoma (ALCL), particularly focusing on the ALK- subtype and breast implant-associated ALCL. The team is using advanced techniques like CRISPR screening to uncover the molecular characteristics of these lymphomas, aiming to identify new therapeutic targets. By understanding how the IL-1R-MyD88 pathway supports the growth of these cancer cells, the researchers hope to develop targeted therapies that could improve treatment outcomes for patients. This approach is designed to address the limitations of current aggressive treatment regimens that are less effective for ALK- ALCL patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Anaplastic Large Cell Lymphoma, especially those with the ALK- subtype or breast implant-associated ALCL.
Not a fit: Patients with ALK+ Anaplastic Large Cell Lymphoma or other unrelated cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective targeted therapies for patients with Anaplastic Large Cell Lymphoma, particularly those with the ALK- subtype.
How similar studies have performed: Other research has shown promise in targeting specific pathways in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
Philadelphia, United States
- Research Inst of Fox Chase Can Ctr — Philadelphia, United States (Active)
Researchers
- Principal investigator: Yang, Yibin — Research Inst of Fox Chase Can Ctr
- Study coordinator: Yang, Yibin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.